Media

Orexo Enters an Exclusive Reimbursement Agreement with UnitedHealth Group and OptumRx for ZUBSOLV®

Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders

Nordic Nanovector´s Betalutin™ granted Orphan Designation in Europe

INDUSTRIFONDEN JOINS GLIONOVA SEK 42 MILLION ($5.7 MILLION) FINANCING CO-LED BY HEALTHCAP AND NOVO

INDUSTRIFONDEN JOINS GLIONOVA SEK 42 MILLION ($5.7 MILLION) FINANCING CO-LED BY HEALTHCAP AND NOVO TO TAKE NOVEL THERAPY FOR GLIOBLASTOMA INTO CLINIC

Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

OxThera initiates clinical trial in Primary Hyperoxaluria

Nordic Nanovector presented phase I study data reporting promising clinical activity

Nordic Nanovector presented phase I study data reporting promising clinical activity in patients with relapsed non-Hodgkin lymphoma at ASH

Nordic Nanovector intends to undertake private placement of NOK 150 million